Futura Medical products

MED3000 is a topically applied gel which utilises our proprietary  DermaSys^® technology, developed specifically for treatment of ED.  MED3000 has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.

TIB200 is a topical 10% ibuprofen gel for pain relief that utilises Futura`s DermaSys^® technology. DermaSys^® enables ibuprofen to be delivered rapidly and efficiently through the skin.  Local application and rapid, efficient absorption translate into a fast onset of action, and the potential for twice-daily dosing.

Scientific advisory meeting held with MHRA confirming the need of a Phase 3 study to support the improved skin permeation including potential superior efficacy claims. Exploring the feasibility of a clinical study to satisfy the Phase 3 requirements for both UK and US approval. Development currently on hold.

Joint venture collaboration. Early development stage completed. IP application filed. Advisers retained to explore commercial opportunities.